[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"corticobasal-degeneration-cbd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:corticobasal-degeneration-cbd":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,63,96,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":44,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100565858","the-curepsp-genetics-program-100565858",false,"NCT06647641","The CurePSP Genetics Program","Inclusion Criteria:\n\n1. Adults (aged 35 or older) with a clinical diagnosis of PSP, CBS, MSA, or a related neurological disease as confirmed by their healthcare provider, or unaffected family members of participants who have reported a family history of relevant neurodegenerative conditions.\n2. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Possible or Probable PSP (32), clinically established or clinically probable MSA (33), Armstrong criteria (2013) for possible or probable CBS (34). Diagnostic certainty will be determined by the treating\u002Freferring clinician.\n3. Willingness to undergo genetic testing. Participants will have the option to receive relevant genetic test results.\n4. Have the capacity to give full informed consent in writing or electronically, or provide consent through a legally authorized representative (LAR)\u002Fpower of attorney (POA), and have read, understood, and completed the informed consent form.\n5. Are able to perform or have a designee who can perform study activities (including completion of either online or orally administered surveys).\n\nExclusion Criteria:\n\n1. Individuals who have received a blood transfusion within the past 3 months.\n2. Individuals who have active hematologic malignancies such as lymphoma or leukemia.\n3. Individuals who have had a bone marrow transplant within the past 5 years.\n4. Individuals under the age of 35 or age of majority in applicable states at the time of consenting.",true,"ALL","35 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.\n\nUp to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"PSP","PSP - Progressive Supranuclear Palsy","Corticobasal Syndrome","Corticobasal Syndrome(CBS)","Corticobasal Degeneration Syndrome","Corticobasal Degeneration","Corticobasal Degeneration (CBD)","Corticobasal Syndrome (CBS)","MSA","MSA - Multiple System Atrophy","MSA-C","Multiple System Atrophy","Multiple System Atrophy (MSA) With Orthostatic Hypotension","Multiple System Atrophy - Cerebellar Subtype (MSA-C)","Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy, Parkinsonian Type","Progressive Supranuclear Palsy","Progressive Supranuclear Palsy(PSP)","Progressive Supranuclear Palsy (PSP)",[45,41,35,46,47,24,32,48,49],"genetic study","Corticobasal","CurePSP","CBD","Genes","RECRUITING","2026-01-12",{"date":53,"type":54},"2026-01-14","ACTUAL",{"date":56,"type":54},"2024-10-08",{"date":58,"type":20},"2030-12-31",{"name":60,"class":61},"Massachusetts General Hospital","OTHER",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":15,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100390419","artfl-lefftds-longitudinal-frontotemporal-lobar-degeneration-allftd-100390419","NCT04363684","ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)","Longitudinal Arm Inclusion Criteria\n\nFamilial FTLD (f-FTLD) participants (either is acceptable):\n\n* members of families in whom at least one member has a known disease-associated mutation in one of the major genes that cause f-FTLD: MAPT, GRN, C9orf72 (or other rare genes)\n* an autosomal dominant family history of a FTLD syndrome (without a known gene) verified by medical record review or well-documented family history including family members with a medical history consistent with FTLD or a related disorder.\n\nSporadic FTLD (s-FTLD) participants:\n\nSporadic participants should be symptomatic with no known family history nor a genetic mutation indicating f-FTLD. All sporadic participants must have an FTLD syndrome as a referring diagnosis; those determined by ALLFTD clinicians to have non-FTLD diagnoses will be excluded from longitudinal visits, but their baseline visit will be included in comparative datasets. For inclusion in the longitudinal follow-up, participants should meet research criteria for one of the following FTLD syndromes:\n\n* Progressive Supranuclear Palsy (PSP)\n* Semantic variant Primary Progressive Aphasia (svPPA)\n* Nonfluent variant Primary Progressive Aphasia (nfvPPA)\n* Corticobasal Degeneration (CBD)\u002FCorticobasal Syndrome (CBS)\n* Behavioral variant Frontotemporal dementia (bvFTD)\n* Frontotemporal Dementia with Amyotrophic Lateral Sclerosis (FTD\u002FALS)\n\nBiofluid-Focused Arm Inclusion Criteria\n\nParticipants enrolled in the biofluid arm may be either f-FTLD or s-FTLD. All general inclusion criteria apply. Participants should meet research criteria (as specified above) for any FTLD syndrome or meet familial FTLD inclusion criteria. Because the biofluid arm participants do not undergo the same detailed clinical and functional assessments required for the longitudinal arm, participants may be included regardless of primary language, as long as an appropriately translated consent is available.\n\nExclusion Criteria:\n\n* Known presence of a structural brain lesion (e.g. tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic participant.\n* Known presence of an Alzheimer's disease causing mutation in PSEN1, PSEN2 or APP; or biomarker evidence for Alzheimer's disease as a cause of the clinical syndrome.\n* A previous history of Korsakoff encephalopathy, severe alcohol dependence (within 5 years of onset of dementia), frequent alcohol or other substance intoxication, or other neurological disorder.\n* Evidence through history or laboratory testing of uncorrected B12 deficiency (B12 \\\u003C 95% of local laboratory's normal value), unregulated hypothyroidism (TSH \\>150% of normal), HIV positive, renal failure (creatinine \\> 2), liver failure (ALT or AST \\> two times normal), respiratory failure that requires supplemental oxygen, large confluent white matter lesions, significant systemic medical illnesses such as deteriorating cardiovascular disease.\n* Current medication likely to affect CNS functions in the opinion of the site PI.\n* In the site investigator's opinion, the participant cannot complete sufficient key study procedures. The participant may be enrolled into the biofluid-focused arm if they can tolerate a blood draw and short clinical exam, but must be able to complete at least 75% of study procedures for enrollment into the longitudinal arm.","18 Years",{"count":71,"type":20},2100,"ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.",[74,43,30,75,76,77,78,79,80,81,82,83,84,85],"Frontotemporal Lobar Degeneration (FTLD)","Behavioral Variant Frontotemporal Dementia (bvFTD)","Semantic Variant Primary Progressive Aphasia (svPPA)","Nonfluent Variant Primary Progressive Aphasia (nfvPPA)","FTD With Amyotrophic Lateral Sclerosis (FTD\u002FALS)","Amyotrophic Lateral Sclerosis","Oligosymptomatic PSP (oPSP)","C9orf72","GRN Related Frontotemporal Dementia","MAPT Gene Mutation","TBK1 Gene Mutation","Oligosymptomatic Progressive Supranuclear Palsy","2025-07-08",{"date":88,"type":54},"2025-07-11",{"date":90,"type":54},"2020-03-01",{"date":92,"type":20},"2026-06-30",{"name":94,"class":61},"Mayo Clinic",27,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":15,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":62},"100593008","imaging-studies-in-corticobasal-syndrome-100593008","NCT07000851","Imaging Studies in Corticobasal Syndrome","Neuroinflammation, White Matter Integrity, AD Biomarkers and Pathology in Corticobasal Syndrome","I-CAN","Inclusion Criteria:\n\n* Age 18 years or older\n* Meet possible or probable CBS criteria\n\nExclusion Criteria:\n\n* Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc)\n* Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome\n* Subjects will be excluded if they have a mutation in the progranulin gene\n* Subjects will excluded if they have received anti-Aβ therapy\n* Women who are pregnant will be excluded\n* Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc)\n* Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid\u002Fglucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning",{"count":105,"type":20},80,"The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.",[108,26,27,29,30,31],"Cortico Basal Degeneration",[110,111,112,113,114,115],"neurodegeneration","neurodegenerative disease","cbs","cbd","corticobasal syndrome","corticobasal degeneration","2025-07-03",{"date":118,"type":54},"2025-07-07",{"date":120,"type":54},"2025-06-25",{"date":122,"type":20},"2031-03-30",{"name":124,"class":61},"Jennifer Whitwell",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":62},"100589088","ai-enhanced-optimization-of-acute-levodopa-challenge-test-100589088","NCT06949865","AI-Enhanced Optimization of Acute Levodopa Challenge Test","Clinical Research on Optimization of Acute Levodopa Challenge Test and Exploration of New Motor Paradigm Based on the Integration of Perception Technology and Artificial Intelligence","Inclusion Criteria:\n\n1. Parkinson's disease (PD) group: 1. Patients with confirmed Parkinson's disease diagnosed based on the 2015 International Movement Disorder Society (MDS) Parkinson's Disease Diagnostic Criteria; 2. Patients with early-stage PD meet the Hoehn-Yahr score ≤ 2.5 points, and patients with intermediate and advanced PD meet the Hoehn-Yahr score of 2.5-5 points; 3. Subjects are 50-75 years old (including boundary values), gender is not limited; 4. Agree to undergo study-related examination evaluation and sign informed consent.\n2. Multiple system atrophy (MSA) group : 1. Patients with confirmed or probable MSA diagnosed based on the diagnostic criteria for MSA published by the International Movement Disorder Society (MDS) in 2022 ;2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n3. Progressive supranuclear palsy (PSP) group: 1. Patients with confirmed or probable PSP diagnosed based on the diagnostic criteria of the 2017 International Movement Disorder Association PSP Collaborative Group; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n4. Vascular parkinsonism (VP) group: 1. In line with the diagnostic recommendations of vascular parkinsonism in accordance with the 2004 International Association for Movement Disorders and the 2017 Chinese expert consensus; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n5. Drug-induced parkinsonism (DIP) group: 1. Parkinsonism; 2. Drug history, the appearance of symptoms is related to specific drugs; 3. Symptoms are reversible, and the symptoms are reduced or disappeared when the corresponding drugs are reduced; 4. Rule out other causes; 5. Subjects are 50-75 years old (including boundary values), gender is not limited; 6. Agree to undergo study-related examination evaluation and sign informed consent.\n6. Corticobasal degeneration (CBD) group: 1. Diagnosis of probable or probable CBD based on the 2019 Chinese diagnostic criteria for corticobasal degeneration; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n7. Dementia with Lewy Bodies (DLB) Group: 1. Diagnosed as probable or possible DLB based on the 2017 international DLB diagnostic criteria and the 2021 Chinese DLB diagnostic criteria. 2. Exhibits symptoms of Parkinsonism. 3. Subjects are aged 50-75 years (inclusive), with no gender restriction. 4. Agree to undergo study-related assessments and evaluations and signs the informed consent form.\n\nExclusion Criteria:\n\n1. Cognitive dysfunction, unable to complete the study (MMSE \\\u003C 23)\n2. Inability to tolerate levodopa shock test\n3. Patients with failure of important organs (heart, lung, liver, kidney, etc.), malignant tumors, unstable conditions and other serious internal diseases\n4. Those with serious behavioral problems or mental disorders\n5. Inability to sign informed consent\n6. Other conditions that are considered unsuitable by the investigator to participate in this study.","50 Years","75 Years",{"count":135,"type":20},2000,"A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence. Combined with traditional motor paradigms and the acute levodopa challenge test, this study aims to identify diagnostic cut-off values for PD and other atypical parkinonism, explore digital biomarkers for early and differential diagnosis, and establish a corresponding diagnostic model.",[138,139,30,140,141,42,142],"Vascular Parkinsonism","Drug-induced Parkinsonism","Parkinson Disease (PD)","Dementia With Lewy Body Disease","Multiple System Atrophy (MSA)","2025-04-22",{"date":145,"type":54},"2025-04-29",{"date":147,"type":54},"2024-05-28",{"date":149,"type":20},"2026-12-31",{"name":151,"class":61},"Beijing Tiantan Hospital"]